TDM for Optimized Outcome in Patients With mRCC.

NCT04659343 · clinicaltrials.gov ↗

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Kidney Cancer
Renal Cell Carcinoma Metastatic
Drug Toxicity
Drug Side Effect
Drug Mechanism

Interventions

OTHER: Measurement of concentration of active metabolite in cancer treatment.

Sponsor

Niels Fristrup

Collaborators

[object Object]
[object Object]